U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Esophageal Carcinoma

MedGen UID:
1755850
•Concept ID:
C5419203
•
Neoplastic Process

Definition

Esophageal carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Esophageal Carcinoma

Professional guidelines

PubMed

Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib.
Li S, Wang H
Drug Des Devel Ther 2023;17:3429-3437. Epub 2023 Nov 15 doi: 10.2147/DDDT.S426898. PMID: 38024530Free PMC Article
Cryotherapy in the management of premalignant and malignant conditions of the esophagus.
Lal P, Thota PN
World J Gastroenterol 2018 Nov 21;24(43):4862-4869. doi: 10.3748/wjg.v24.i43.4862. PMID: 30487696Free PMC Article
Current treatment options for esophageal diseases.
Martínek J, Akiyama JI, Vacková Z, Furnari M, Savarino E, Weijs TJ, Valitova E, van der Horst S, Ruurda JP, Goense L, Triadafilopoulos G
Ann N Y Acad Sci 2016 Oct;1381(1):139-151. Epub 2016 Jul 8 doi: 10.1111/nyas.13146. PMID: 27391867

Recent clinical studies

Therapy

Precision medicine for human cancers with Notch signaling dysregulation (Review).
Katoh M, Katoh M
Int J Mol Med 2020 Feb;45(2):279-297. Epub 2019 Dec 4 doi: 10.3892/ijmm.2019.4418. PMID: 31894255Free PMC Article
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y
Lancet Oncol 2019 Nov;20(11):1506-1517. Epub 2019 Sep 30 doi: 10.1016/S1470-2045(19)30626-6. PMID: 31582355
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K
Lancet Oncol 2017 Nov;18(11):1512-1522. Epub 2017 Oct 13 doi: 10.1016/S1470-2045(17)30604-6. PMID: 29037983
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Prognosis

Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.
Fichtl A, Seufferlein T, Zizer E
BMC Gastroenterol 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0. PMID: 37986043Free PMC Article
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K
Lancet Oncol 2017 Nov;18(11):1512-1522. Epub 2017 Oct 13 doi: 10.1016/S1470-2045(17)30604-6. PMID: 29037983
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Caustic ingestion in children-A review.
Arnold M, Numanoglu A
Semin Pediatr Surg 2017 Apr;26(2):95-104. Epub 2017 Feb 3 doi: 10.1053/j.sempedsurg.2017.02.002. PMID: 28550877
Current treatment options for esophageal diseases.
Martínek J, Akiyama JI, Vacková Z, Furnari M, Savarino E, Weijs TJ, Valitova E, van der Horst S, Ruurda JP, Goense L, Triadafilopoulos G
Ann N Y Acad Sci 2016 Oct;1381(1):139-151. Epub 2016 Jul 8 doi: 10.1111/nyas.13146. PMID: 27391867

Clinical prediction guides

Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.
Saeed A, Park R, Dai J, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Saeed A, Ripp J, Collins Z, Mulvaney K, Shugrue M, Firth-Braun J, Godwin AK, Madan R, Phadnis M, Sun W
Cell Rep Med 2023 Feb 21;4(2):100916. Epub 2023 Jan 25 doi: 10.1016/j.xcrm.2023.100916. PMID: 36702123Free PMC Article
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Caustic ingestion in children-A review.
Arnold M, Numanoglu A
Semin Pediatr Surg 2017 Apr;26(2):95-104. Epub 2017 Feb 3 doi: 10.1053/j.sempedsurg.2017.02.002. PMID: 28550877
Current treatment options for esophageal diseases.
Martínek J, Akiyama JI, Vacková Z, Furnari M, Savarino E, Weijs TJ, Valitova E, van der Horst S, Ruurda JP, Goense L, Triadafilopoulos G
Ann N Y Acad Sci 2016 Oct;1381(1):139-151. Epub 2016 Jul 8 doi: 10.1111/nyas.13146. PMID: 27391867

Recent systematic reviews

Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis.
Gao TT, Shan JH, Yang YX, Zhang ZW, Liu SL, Xi M, Liu MZ, Zhao L
BMC Cancer 2022 Sep 17;22(1):992. doi: 10.1186/s12885-022-10086-5. PMID: 36115960Free PMC Article
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, Shah MA, Rha SY, Ohtsu A, Liepa AM, Knoderer H, Chatterjee A, Van Cutsem E
Oncologist 2021 Oct;26(10):e1704-e1729. Epub 2021 Sep 3 doi: 10.1002/onco.13907. PMID: 34288262Free PMC Article
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Saeed A, Park R, Sun W
J Hematol Oncol 2021 Jan 12;14(1):13. doi: 10.1186/s13045-021-01034-0. PMID: 33436042Free PMC Article
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T
Cochrane Database Syst Rev 2020 Nov 19;11(11):CD012078. doi: 10.1002/14651858.CD012078.pub2. PMID: 33210731Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...